Compare Cytokinetics Inc (CYTK) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Snap On Incorporated — how do they compare? Cytokinetics Inc trades at $76.73 (market cap $10.63B), while Snap On Incorporated trades at $407.8 (market cap $21.30B). The key difference: Snap On Incorporated is far larger — about 2× Cytokinetics Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SNA | |
|---|---|---|
Market Cap | $10.63B | $21.30B |
Sector | Technology | Technology |
52-Week High | $87.26 | $419.31 |
52-Week Low | $34.31 | $321.38 |
Enterprise Value | $10.74B | $20.93B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Snap-on (SNA) trades at $407.04, down 0.99% today, with a bullish technical signal from moving averages and support near $406. The company reported strong Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% and a net income margin of 19.6%. Recent acquisitions like Diesel Laptops for $100 million aim to expand its diagnostics reach.
The outlook remains positive with a consensus price target of $455.33, implying 12% upside, supported by robust cash flow and dividend payments. Key risks include integration costs from acquisitions and premium valuation multiples, while softer OEM demand and economic sensitivity could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
